ESR1 and breast carcinoma: Currently, enobosarm is being evaluated as a monotherapy in clinical trials for multiple pathologies, including ER-positive/AR-positive breast cancer as well as AR-positive TNBC breast cancer (NCT01616758, NCT02463032, and NCT04869943).